

ONCOLOGY CLINICAL TRIALS AT TIDALHEALTH

Breast	Lung
<p>A011502 (ABC) – A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer</p>	<p>A151216 – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial. Criteria: Patients with Resectable or Resected Lung Cancer</p>
<p>A011401 – Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer</p>	<p>A081105 – Randomized Double-Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer</p>
<p>A221505 – Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast. Criteria: Post Mastectomy Radiation Therapy with Breast Reconstruction</p>	<p>Investigator Initiated (BH03) –Body Mass Index (BMI) and Lung Cancer Recurrence.</p>
<p>EA1131 – A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy Residual</p>	<p>E4512 – A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein</p>
<p>S1418/NRG-BR006 – A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer</p>	<p>NRG-CC003 – Randomized Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer</p>
	<p>LungMAP – A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer</p>
	<p>S1900A – A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutations Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP SUB-STUDY)</p>
Colon	Prostate
<p>A021502 – Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy Criteria: Stage III Colon Cancer and Deficient DNA Mismatch Repair</p>	<p>NRG-GU002 – Phase II/III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following RP with or without Adjuvant Docetaxel Criteria: Post Radical Prostatectomy Radiotherapy and Androgen Deprivation</p>
	<p>NRG-GU005 – Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer</p>
All Types of Cancers	
<p>Johns Hopkins Clinical Research Network – Communication Skills Training for Cancer Patients and their Care Partners.</p>	
<p>Investigator Initiated – A case-control study evaluating well water use among cancer patients on the Lower Eastern Shore of Maryland</p>	